Table 1 Preclinical studies using HLMSCs or HLMSC-CM to treat liver diseases
From: Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases
Cell type | Number of cells infused | Model | Animal | Administration route | Follow-up period | Efficacy | Ref. |
|---|---|---|---|---|---|---|---|
LHMSCs | 2.5 × 106 | Rigler-Najjar type I syndrome | Gunn rats | iv (portal vein) | 6 months | Decrease in bilirubin level | [64] |
LHMSCs | 1 × 106 | 20 % hepatectomy | SCID mice | ip | 60 days | Proliferation and differentiation of LHMSCs in vivo | [66] |
LHMSCs | 1 × 106 | 70 % partial hepatectomy | uPA+/+-SCID, SCID mice | ip | 56 days | Proliferation and differentiation of LHMSCs in vivo | [19] |
LHMSC-CM | – | 70 % partial hepatectomy | C57BL/6 mice | Not mentioned | 2 days | Enhanced liver regenerative responses | [73] |
LHMSCs | 5 × 105 | Liver fibrosis | NOD/SCID/IL-2Rγ (null) mice | iv (tail vein) | 8 weeks | No benefits observed | [87] |
LHMSCs | 2 × 105 | Acute liver injury | SCID mice | iv | 30 days | Proliferation of LHMSCs in vivo | [22] |
LHMSCs from liver graft preservation fluids | 1× 106 | Acute liver injury | NOD/SCID mice | ip | 4 weeks | Differentiation of LHMSCs in vivo | [20] |
MSCs, LHMSC-CM | 2 × 106 (iv), 3 × 107 (ip), 5 × 105 or 2 × 105 (LP) | Acute liver failure | SCID mice | iv, ip, LP | 21 days | Increased survival rates, decrease in liver metabolic enzymes and ammonium | [81] |